Topics:
Radiation Oncology • Melanoma/Skin Cancer • Medical Oncology • Non-melanoma skin cancer • Journal Club ft. NEJM publications • Dermatology • Cutaneous Squamous Cell Carcinoma
Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?
Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?
Answer from: Radiation Oncologist at Academic Institution
No
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Cutaneous squamous cell carcinoma (CSCC) most often arises in sun-exposed areas such as the head and neck regions. While surgical excision in these areas may be technically feasible, they may also be associated with cosmetic disfigurement, impaired function, and inadequate oncologic control. Most CS...
Answer from: Medical Oncologist at Community Practice
Patients with such cancer are usually referred to surgeons or dermatologists first. Through recent multidisciplinary conferences, we are now slowly switching treatment to a systemic neoadjuvant approach, more specifically with cemiplimab.Rationale for this study: I am quoting the introduction of the...
Answer from: Medical Oncologist at Community Practice
As mentioned before, we are selectively using 'neoadjuvant' cemiplimab. More commonly, patients start therapy for unresectable disease, have a deep response, and we occasionally consider consolidative surgery when they achieve maximal response. This same paradigm is used for cutaneous squamous cell ...
Comments
Radiation Oncologist at Summit Medical Center
The patients described have "locally advanced or u...
The patients described have "locally advanced or u...
at LindaSusan Marcus, MD
If surgery is not an option, radiation is a consid...
If surgery is not an option, radiation is a consid...